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Introduction 4 6
Glutathione S-transferase µ 1 (GSTM1), belongs to the family of glutathione-S-transferases that 4 7 metabolize a broad range of reactive oxygen species and aldehydes. 1,2 Loss of GSTM1 is very common in 4 8 the population; approximately 50% of whites and 27% of blacks have zero copies of GSTM1. 3 Deletion of 4 Discussion 1 1 0
To our knowledge, this is the largest study to investigate the association of GSTM1 copy number variation 1 1 1 with kidney failure. There were a total of 46,187 unrelated whites and 796 blacks in the study with an 1 1 2 average of 9.3 years' follow-up. The frequency of the GSTM1copy numbers were very similar to those 1 1 3 reported previously. 3, 5, 6 Our results showed no significant association between GSTM1 copy number and 1 1 4 risk of kidney failure in unadjusted or adjusted analyses whether using a genotypic, dominant, or 1 1 5 recessive genetic model. 1 1 6
Data from the ARIC and AASK cohorts suggested that the loss of GSTM1 increased the risk of kidney 1 1 7 failure or accelerated CKD progression. 5, 6, 17 In ARIC, a community-based cohort of middle-aged black 1 1 8 and white participants, there were 3461 white participants with WES reads. In fully adjusted models 1 1 9 among whites in ARIC, loss of GSTM1 was associated with risk of kidney failure (0 or 1 copy vs. 2 1 2 0 copies: HR 2.54; 95% CI: 1. 32-4.88) . It is possible that differences in baseline characteristics of the study 1 2 1 populations could explain differing findings. Our cohort had a lower prevalence of smoking (never 1 2 2 smoking 48% vs. 38%), a higher prevalence of diabetes (14% vs. 8%), and was more contemporary 1 2 3 (median baseline year 2004 (median baseline year vs. ARIC baseline year 1987 (median baseline year -1989 . However, in sensitivity analyses in 1 2 4 14572 white participants with baseline year between 1996-2002 in our cohort, there was no association 1 2 5 between GSTM1 loss and risk of kidney failure. 1 2 6
There is also the possibility that GSTM1 may only be deleterious when GFR falls below certain levels, or 1 2 7 in the setting of specific types of kidney disease. In the AASK study, a randomized trial comparing 1 2 8 different antihypertensive medications and levels of blood pressure control in blacks with CKD attributed 1 2 9 to hypertension, 692 participants had GSTM1 genotyping completed. Loss of GSTM1 in AASK was 1 3 0 associated with increased risk of CKD progression (HR 0 copy: HR 1.88; 95% CI: 1.07-3.30; HR 1 copy: 1 3 1 1.68; 95% CI: 1.00-2.84). While there were few blacks in our study population with CKD, we found no 1 3 2 association between loss of GSTM1 and risk of kidney failure in 3129 white participants with baseline 1 3 3 eGFR < 60 ml/min/1.73m 2 . Some smaller case-control studies also tested a recessive genetic model (0 1 3 4 copies vs. 1 or 2 copies) of GSTM1 and found that GSTM1 0 copy was associated with kidney failure in 1 3 5 several case-control studies. 5, 10, 11, 18 In our study, however, we examined both recessive and dominant 1 3 6 genetic models, and found no associations between GSTM1 copy number and risk of kidney failure. 1 3 7 Some limitations of this study are worth noting. First, the genotypes of GSTM1 in this study were derived 1 3 8 from WES and the thresholds were determined empirically from the histogram. Multiplex PCR validation 1 3 9
was not performed for this study. However, this method was used in the ARIC study, which showed 1 4 0 99.3% agreement when comparing the results of 0 copy with ≥ 1 copy from PCR. 6 Moreover, the 1 4 1 frequency of GSTM1 copy numbers in this study is similar to those reported previously for both whites 1 4 2 and blacks, 5,6 and it follows the Hardy-Weinberg equilibrium. We also examined the possibility of miss-1 4 3 mapping due to the complexity of GSTM locus. The histogram of the sum of normalized coverage of 1 4 4 GSTM5, the paralog gene of GSTM1, is unimodal distribution. Based on these evidences, we believe the 1 4 5 copy number results derived from WES had a low error rate and can be used with confidence for analysis. 1 4 6
Second, the sample size for blacks was small with only 796 patients available for analysis, limiting the 1 4 7 power to examine an association between GSTM1 and kidney failure in this population. The strength of 1 4 8 this study is the large sample size of whites, which included 46,187 patients, allowing for large subgroup 1 4 9 analyses in older patients, those with baseline eGFR < 60 ml/min/1.73m 2 , and those with longer duration 1 5 0 of follow-up. Finally, GSTM1 deletion is known to be protective for lung cancer among individuals with a 1 5 1 high intake of cruciferous vegetable and deleterious among those with low intake of cruciferous 1 5 2 vegetable.
We were not able to analyze the effect modification between GSTM1 copy number and 1 5 3 cruciferous vegetable intake. 1 5 4
In conclusion, our study does not support an association between loss of GSTM1 and increased risk of 1 5 5 kidney failure. Additional research is needed to confirm whether loss of GSTM1 increases risk of kidney 1 5 6 failure in certain subgroups such as blacks, and the interaction with diet. The study population included 72,756 participants in the Geisinger-Regeneron DiscovEHR cohort with 1 6 1 WES data and at least 3 serum creatinine values. We excluded participants who had baseline eGFR < 15 1 6 2 ml/min/1.73m 2 or history of dialysis or transplant (n=417), baseline age <18 (n=1,960), missing BMI 1 6 3 values (n=230), and unknown smoking status (n=2,694). Cryptic relatedness was evaluated using IBD 1 6 4 method in PLINK1.9. 24 One of the related pair of participants with PI_HAT >= 0.125 were removed to 1 6 5 reduce confounding from other shared genetic/environmental factors that could not be assessed, resulting 1 6 6 in 46983 participants (Supplement Figure 1 ). We estimated eGFR using the CKD-Epidemiology 1 6 7
Collaboration equation. 25, 26 We defined the study period, from a baseline time of the second serum 1 6 8 creatinine to the time of a renal endpoint, or the last serum creatinine test. All participants provided their 1 6 9 informed written consent, and the study was approved by the Geisinger Institutional Review Board. 1 7 0
Outcome definition 1 7 1 An assignment of kidney failure was made if any of the following criteria was met: 1) the last available 1 7 2 eGFR was less than 15 mL/min/1.73 m 2 ; 2) the EHR showed an International Classification of Disease 1 7 3 (ICD) code for end stage renal disease (ESRD) (ICD9: 585.6, ICD10: N18.6); 3) receipt of dialysis or 1 7 4 transplant per linkage to the United States Renal Data System (USRDS). For participants who met more 1 7 5 than one criteria, the earliest documented date of the criterion was considered the kidney failure date. 1 7 6
Clinical variables 1 7 7
The following data elements were extracted from the EHR: baseline age, sex, self-reported race, body 1 7 8 mass index (BMI, BMI = Weight(kg)/Height(m) 2 ), serum creatinine, smoking status; and ICD-9/10 coded 1 7 9 diagnosis of hypertension, diabetes, coronary artery disease, heart failure, and stroke. Genetic principal 1 8 0 components were calculated by PLINK1.9 (www.cog-genomics.org/plink/1.9/). 24 1 8 1 GSTM1 and GSTM5 copy number estimation 1 8 2 DNA was sequenced in two batches at the Regeneron Genetic Center. The WES data processing has been 1 8 3 described elsewhere, 13, 15 and details are also provided in the supplementary methods. Copy number of 1 8 4 GSTM1 was estimated using the method reported previously. 6 Briefly, sequence coverage was normalized 1 8 5 using CLAMMS software. 27 Normalized coverage of all eight exons of GSTM1 was summed for each 1 8 6 participant. Thresholds for GSTM1 copy number were determined empirically according to the 1 8 7 distribution of sum of normalized coverage (Supplementary Figure 2) . The copy number of GSTM5 was 1 8 8 estimated the same way as GSTM1 (Supplementary notes). 1 8 9
Statistical analyses 1 9 0
Hardy-Weinberg equilibrium (HWE) was estimated using Chi-Square test for GSTM1 copy number. A 1 9 1 more stringent significance level of 1e -5 was selected due to the large sample size (46,187) for Whites. 1 9 2
Nominal significance level of 0.05 was used for Blacks as the small sample size (796). Missing baseline 1 9 3 BMI values were imputed using mean BMI values calculated from all available BMI values for each 1 9 4 participant, and missing smoking status at baseline was imputed using the most recent recorded smoking 1 9 5 status in the EHR (Supplemental Figure 3) . Baseline characteristics were compared using ANOVA for 1 9 6 continuous variables, and chi-squared tests for categorical variables. A p-value of < 0.05/N was 1 9 7 considered statistically significant after Bonferroni adjustment for multiple comparisons, where N is the 1 9 8 number of variables compared. Kaplan-Meier curves were plotted by GSTM1 copy number, and survival 1 9 9 differences between genotype groups were assessed using a log rank test. All subsequent analyses were 2 0 0 stratified by race given the difference in allele frequency and sample size. Two models were evaluated. In 2 0 1 Model 1, Cox proportional hazards model was adjusted for age, sex and the first four genetic principle 2 0 2 components; Based on Model 1, Model 2 was additionally adjusted for risk factors including baseline 2 0 3 eGFR, smoking status, BMI, hypertension, diabetes, coronary artery disease, heart failure and stroke. 2 0 4
Three genetic models were evaluated: 1) genotypic model, using copy number 0,1, and 2 as three 2 0 5 categories; 2) dominant model (0 or 1 copy vs. 2 copies GSTM1); 3) recessive model (1 or 2 copies vs. 0 2 0 6 copies of GSTM1). To explore whether the effect of GSTM1 loss was stronger in specific higher-risk 2 0 7 subgroups, sensitivity analyses were completed including subsets of 1) older participants (baseline age ≥ 2 0 8 45 years); 2) participants with CKD (baseline eGFR < 60 ml/min per 1.73 m 2 ); 3) participants with longer 2 0 9 follow-up (baseline year 1996-2002) . Power was estimated using powerCT() function in R package 2 1 0 powerSurvEpi 0.1.0. Given the current sample size and event number, we have power of >=0.8 to test 2 1 1 hazard ratio of at least 1.4 and 2.8 for white and black cohort, respectively. All analyses were performed 2 1 2 using R (version 3.4.3 1  5  3  4  -2  6  2  1  5  3  6  .  2  6  3   1  7  .  B  o  d  o  n  y  i  -K  o  v  a  c  s  G  ,  M  a  J  Z  ,  C  h  a  n  g  J  ,  e  t  a  l  .  C  o  m  b  i  n  e  d  E  f  f  e  c  t  s  o  f  G  S  T  M  1  N  u  l  l  A  l  l  e  l  e  a  n  d  A  P  O  L  1  R  e  n  a  l  2  6  4  R  i  s  k  A  l  l  e  l  e  s  i  n  C  K  D  P  r  o  g  r  e  s  s  i  o  n  i  n  t  h  e  A  f  r  i  c  a  n  A  m  e  r  i  c  a  n  S  t  u  d  y  o  f  K  i  d  n  e  y  D  i  s  e  a  s  e  a  n  d  2  6  5  H  y  p  e  r  t  e  n  s  i  o  n  T  r  i  a  l  .   J  A  m  S  o  c  N  e  p  h  r  o  l  .   2  0  1  6  ;  2  7  (  1  0  )  :  3  1  4  0  -3  1  5  2  .  2  6  6  1  8  .  S  u  v  a  k  o  v  S  ,  D  a  m  j  a  n  o  v  i  c  T  ,  S  t  e  f  a  n  o  v  i  c  A  ,  e  t  a  l  .  G  l  u  t  a  t  h  i  o  n  e  S  -t  r  a  n  s  f  e  r  a  s  e  A  1  ,  M  1  ,  P  1  a  n  d  T  1  n  u  l  l  o  r  2  6  7  l 
